Treatment Response Analysis
| 3 mo | 6 mo | |||||||
| Criteria | Survival (mo) | HR | R2 (%) | P | Survival (mo) | HR | R2 (%) | P |
| RECIST | 1 | — | — | 0.27 (0.03–2.08) | 13 | 0.207 | ||
| R | — | 26 | ||||||
| NR | 20 | 22 | ||||||
| WHO | 0.76 (0.16–3.50) | 0 | 0.723 | 0.47 (0.13–1.76) | 8 | 0.264 | ||
| R | 24 | 26 | ||||||
| NR | 12 | 18 | ||||||
| mRECIST | 0.27 (0.07–1.01) | 21 | 0.052 | 0.15 (0.04–0.60) | 40 | 0.007 | ||
| R | 26 | 27 | ||||||
| NR | 11.5 | 11.5 | ||||||
| EASL | 0.30 (0.10–0.95) | 20 | 0.040 | 0.22 (0.07–0.75) | 29 | 0.016 | ||
| R | 26 | 26 | ||||||
| NR | 11 | 11.5 | ||||||
| RECIST | 0.16 (0.02–1.65) | 8 | 0.124 | 0.24 (0.05–1.24) | 13 | 0.088 | ||
| DC | 23 | 25.5 | ||||||
| PD | 7.5 | 14 | ||||||
| WHO | 0.23 (0.04–1.24) | 10 | 0.088 | 0.24 (0.05–1.24) | 13 | 0.088 | ||
| DC | 24 | 25.5 | ||||||
| PD | 8 | 14 | ||||||
| mRECIST | 0.22 (0.04–1.15) | 12 | 0.072 | 0.51 (0.06–4.27) | 2 | 0.537 | ||
| DC | 24 | 25 | ||||||
| PD | 9.5 | 22 | ||||||
| EASL | 0.22 (0.04–1.15) | 12 | 0.072 | 0.07 (0.01–0.56) | 27 | 0.011 | ||
| DC | 24 | 25.5 | ||||||
| PD | 9.5 | 8.5 | ||||||
R = responders; NR = nonresponders; DC = disease control; PD = progressive disease.
Data in parentheses are 95%CI.